Arch Therapeutics to Present at 2015 LD MICRO Invitational Conference on June 1
May 18, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 18, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
April 16, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 16, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Fibrin Sealant
April 14, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 14, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
March 25, 2015 07:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Mar 25, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
March 23, 2015 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Mar 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Cabot Microelectronics to Hold Annual Meeting of Stockholders on March 3
February 24, 2015 06:00 ET
|
CMC Materials
Aurora, IL, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Cabot Microelectronics Corporation (Nasdaq:
CCMP), the world's leading supplier of chemical mechanical
planarization (CMP) polishing slurries and a...
Pre-Clinical Animal Pilot Study Shows Arch Therapeutics' AC5(TM) Compared Favorably Versus a Popular Hemostatic Agent
February 23, 2015 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for use in bleeding during...
Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
February 19, 2015 08:56 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 19, 2015) - Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"),...
The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
February 17, 2015 08:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 17, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a medical device company and developer of the AC5 Surgical Hemostatic Device™...
Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
January 13, 2015 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 13, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results when...